First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

But it remains to be seen how long this can continue because of dwindling sales of its inflammatory disease drug Remicade and a looming threat to Zytiga. Zytiga (abiraterone), approved since 2011 ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

The charity is urging NICE and Johnson & Johnson (J&J) subsidiary Janssen to return to the negotiating table to try to thrash out an agreement on Zytiga's pricing that would allow the drug to be ...

Drug developers are working on next-generation ... the androgen biosynthesis inhibitor abiraterone (Zytiga) and Arvinas’s first-generation and now-discontinued AR-degrader bavdegalutamide, ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...

Zytiga treats metastatic prostate cancer by reducing male hormone production, slowing tumor growth. The drug is FDA-approved for both hormone-resistant and hormone-sensitive metastatic prostate cancer ...

The first patient has been dosed in a phase 1b/2a trial (NCT06785636) of pocenbrodib, a CBP/p300 inhibitor, as a monotherapy and in combination with abiraterone acetate (Zytiga), olaparib ... or other ...